{"title":"肝细胞癌患者是乙型肝炎免疫检查点抑制剂的理想研究人群","authors":"Guanglin Xiao, Hong Ren","doi":"10.1016/j.jhep.2024.10.010","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>This work was supported by a Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University</section></section><section><section><h2>Authors’ contributions</h2>G.X.: Manuscript writing & Study design. H.R.: Manuscript revision & Study design.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors do not have any disclosures to report.Please refer to the accompanying ICMJE disclosure form for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B\",\"authors\":\"Guanglin Xiao, Hong Ren\",\"doi\":\"10.1016/j.jhep.2024.10.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Financial support</h2>This work was supported by a Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University</section></section><section><section><h2>Authors’ contributions</h2>G.X.: Manuscript writing & Study design. H.R.: Manuscript revision & Study design.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors do not have any disclosures to report.Please refer to the accompanying ICMJE disclosure form for further details.</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.010\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.010","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B
Section snippets
Financial support
This work was supported by a Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University
Authors’ contributions
G.X.: Manuscript writing & Study design. H.R.: Manuscript revision & Study design.
Declaration of Competing Interest
The authors do not have any disclosures to report.Please refer to the accompanying ICMJE disclosure form for further details.
期刊介绍：
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
